Related references
Note: Only part of the references are listed.Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response
Laura Valerio et al.
ENDOCRINE-RELATED CANCER (2020)
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Charles Pottier et al.
CANCERS (2020)
Destructive thyroiditis presenting as thyrotoxicosis followed by hypothyroidism during lenvatinib therapy for hepatocellular carcinoma
Maito Suoh et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2020)
Destructive Thyroiditis Induced by Lenvatinib in Three Patients with Hepatocellular Carcinoma
Masashi Hirooka et al.
INTERNAL MEDICINE (2019)
Properties of FDA-approved small molecule protein kinase inhibitors
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Paradigms of Dynamic Control of Thyroid Hormone Signaling
Antonio C. Bianco et al.
ENDOCRINE REVIEWS (2019)
Gain-of-Function Mutations: An Emerging Advantage for Cancer Biology
Yongsheng Li et al.
TRENDS IN BIOCHEMICAL SCIENCES (2019)
Deiodinases and their intricate role in thyroid hormone homeostasis
Cristina Luongo et al.
NATURE REVIEWS ENDOCRINOLOGY (2019)
Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders
Arnaud Jannin et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
Mechanisms of receptor tyrosine kinase activation in cancer
Zhenfang Du et al.
MOLECULAR CANCER (2018)
Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors
Wagner Ricardo Montor et al.
MOLECULAR CANCER (2018)
Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers
Melissa G. Lechner et al.
THYROID (2018)
Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors
Perrine Buffier et al.
ANNALES D ENDOCRINOLOGIE (2018)
Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma
Carolien M. Beukhof et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life
Antonio Matrone et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
Chemistry and Biology in the Biosynthesis and Action of Thyroid Hormones
Santanu Mondal et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Skin problems and EGFR-tyrosine kinase inhibitor
Toshiyuki Kozuki
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2016)
Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses
Mao Shu et al.
PLOS ONE (2016)
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
Douglas S. Ross et al.
THYROID (2016)
Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
Seung-Hoon Beom et al.
CANCER RESEARCH AND TREATMENT (2016)
Thyroid hormone transporters-functions and clinical implications
Juan Bernal et al.
NATURE REVIEWS ENDOCRINOLOGY (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
Fabiana Pani et al.
THYROID (2015)
Risk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis
Omar Abdel-Rahman et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2014)
Interstitial lung disease during targeted therapy in metastatic renal cell carcinoma: a case series from three centres
Philipp Ivanyi et al.
MEDICAL ONCOLOGY (2014)
Thyroid Hormone Inactivation in Gastrointestinal Stromal Tumors
Michelle A. Maynard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sunitinib Does Not Block Thyroid Peroxidase in Patients
Llanyee Liwanpo et al.
THYROID (2014)
Cabozantinib-Induced Thyroid Dysfunction: A Review of Two Ongoing Trials for Metastatic Bladder Cancer and Sarcoma
Sahzene Yavuz et al.
THYROID (2014)
Risk of hypothyroidism in patients with cancer treated with sunitinib: A systematic review and meta-analysis
Tomohiro Funakoshi et al.
ACTA ONCOLOGICA (2013)
Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis
Yi Ling Teo et al.
CANCER TREATMENT REVIEWS (2013)
Sorafenib therapy decreases the clearance of thyrotropin
Herman Verloop et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Inappropriate Elevation of Serum Thyrotropin Levels in Patients Treated with Axitinib
Kenji Ohba et al.
THYROID (2013)
Tyrosine Kinase Inhibitor-Induced Thyroid Disorders: A Review and Hypothesis
Noriko Makita et al.
THYROID (2013)
Mechanisms of TKI-induced diarrhea in cancer patients
Joanne M. Bowen
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE (2013)
Thyroid Dysfunction in Patients Treated with Tyrosine Kinase Inhibitors, Sunitinib, Sorafenib and Axitinib, for Metastatic Renal Cell Carcinoma
Makoto Daimon et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2012)
Tyrosine Kinase Inhibitors Noncompetitively Inhibit MCT8-Mediated Iodothyronine Transport
Doreen Braun et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
Alex Kentsis et al.
NATURE MEDICINE (2012)
Hypothyroidism in Patients With Renal Cell Carcinoma Blessing or Curse?
Manuela Schmidinger et al.
CANCER (2011)
Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer
V. Hirsh
Current Oncology (2011)
Sunitinib-Induced Hypothyroidism Is due to Induction of Type 3 Deiodinase Activity and Thyroidal Capillary Regression
Mariette H. W. Kappers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Mechanistic insights into the activation of oncogenic forms of EGF receptor
Zhihong Wang et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Sorafenib Induced Thyroiditis in Two Patients with Hepatocellular Carcinoma
Leni van Doorn et al.
THYROID (2011)
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib
L. M. Riesenbeck et al.
WORLD JOURNAL OF UROLOGY (2011)
Mechanisms of chromosomal rearrangement in the human genome
Albert G. Tsai et al.
BMC GENOMICS (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination
Randa M. Abdulrahman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Shrinkage of Thyroid Volume in Sunitinib-Treated Patients with Renal-Cell Carcinoma: A Potential Marker of Irreversible Thyroid Dysfunction?
Aljosja Rogiers et al.
THYROID (2010)
Sunitinib Induces Hypothyroidism with a Markedly Reduced Vascularity
Noriko Makita et al.
THYROID (2010)
Thyroid Dysfunction Caused by Second-Generation Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Theo D. Kim et al.
THYROID (2010)
Sunitinib-Induced Thyrotoxicosis Followed by Persistent Hypothyroidism with Shrinkage of Thyroid Volume
Kanako Sakurai et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation
Hideaki Miyake et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2010)
Tyrosine Kinase Inhibitors - A Review on Pharmacology, Metabolism and Side Effects
Joerg Thomas Hartmann et al.
CURRENT DRUG METABOLISM (2009)
Tyrosine kinase inhibitors and modifications of thyroid function tests: a review
Frederic Illouz et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Cardiovascular Complications of Cancer Therapy Incidence, Pathogenesis, Diagnosis, and Management
Edward T. H. Yeh et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy
Francesco Torino et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib
John P. Crown et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
The clinical implications of sunitinib-induced hypothyroidism:: a prospective evaluation
P. Wolter et al.
BRITISH JOURNAL OF CANCER (2008)
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
Mathis Grossmann et al.
CLINICAL ENDOCRINOLOGY (2008)
Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities
Jessica Plati et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
Phase II trial of sorafenib in advanced thyroid cancer
Vandana Gupta-Abramson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Motesanib diphosphate in progressive differentiated thyroid cancer
Steven I. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake
Deborah Mannavola et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Chemotherapy agents and hypertension: A focus on angiogenesis blockade
Manish Jain et al.
CURRENT HYPERTENSION REPORTS (2007)
Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
Elaine Wong et al.
THYROID (2007)
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors
Jayesh Desai et al.
ANNALS OF INTERNAL MEDICINE (2006)
Tyrosine kinase inhibitors causing hypothyroidism in a patient on levothyroxine
J. W. B. de Groot et al.
ANNALS OF ONCOLOGY (2006)
Deiodinases: implications of the local control of thyroid hormone action
Antonio C. Bianco et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Gene amplification in cancer
Donna G. Albertson
TRENDS IN GENETICS (2006)
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
T Kamba et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Consumptive hypothyroidism caused by paraneoplastic production of type 3 iodothyronine deiodinase
MD Ruppe et al.
THYROID (2005)
Role of tyrosine kinase inhibitors in cancer therapy
A Arora et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Imatinib induces hypothyroidism in patients receiving levothyroxinc
JWB de Groot et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Physiology and pathophysiology of type 3 deiodinase in humans
SA Huang
THYROID (2005)
Type 1 iodothyronine deiodinase is a sensitive marker of peripheral thyroid status in the mouse
AM Zavacki et al.
ENDOCRINOLOGY (2005)
Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer
G Selvaggi et al.
ANNALS OF ONCOLOGY (2004)
Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter
ECH Friesema et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Chromosome aberrations in solid tumors
DG Albertson et al.
NATURE GENETICS (2003)
Current concepts: Thyroiditis
EN Pearce et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Role for inner ring deiodination preventing transcutaneous passage of thyroxine
F Santini et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Evidence for a role of the type III-iodothyronine deiodinase in the regulation of 3,5,3′-triiodothyronine content in the human central nervous system
F Santini et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2001)
Cell signaling by receptor tyrosine kinases
J Schlessinger
CELL (2000)
Brief report: Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas.
SA Huang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
